";s:4:"text";s:4791:" If Ponstel is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury.Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. Cardiac or neurologic problems. Do not give NSAIDs to other people, even if they have the same symptoms that you have. The fecal route of elimination accounts for up to 20% of the dose, mainly in the form of unconjugated 3-carboxymefenamic acid.The elimination half-life of mefenamic acid is approximately two hours. This risk may occur early in treatment and may increase with duration of use (NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. If the anticipated benefit for the elderly patient outweighs these potential risks, start dosing at the low end of the dosing range, and monitor patients for adverse effects Clinical studies of Ponstel did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. TRIAL REGISTRATION: Current Controlled Trials ISRCTN01253916.
Because both renal and hepatic excretions are significant pathways of elimination, dosage adjustments in patients with renal or hepatic dysfunction may be necessary. Clinical studies indicate that effective treatment can be initiated with the start of menses and should not be necessary for more than 2 to 3 days.Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. It may harm them.If you would like more information about NSAIDs, talk with your healthcare provider. Most postmarketing reports of fatal GI events occurred in elderly or debilitated patients. Brief storage between 59-86 degrees F (15-30 degrees C) is permitted. Monitor these patients for signs of bleeding Ponstel cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. The relationship of unbound fraction to drug concentration has not been studied.
Although the absolute rate of death declined somewhat after the first year post-MI, the increased relative risk of death in NSAID users persisted over at least the next four years of follow-up.Avoid the use of Ponstel in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. Avoid taking NSAIDs after a recent heart attack, unless your healthcare provider tells you to. Because mefenamic acid is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues.Mefenamic acid is rapidly absorbed after oral administration. Use of mefenamic acid may blunt the CV effects of several therapeutic agents used to treat these medical conditions (e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers [ARBs]) Avoid the use of Ponstel in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If it is near the time of the next dose, skip the missed dose. Patients taking angiotensin converting enzyme (ACE) inhibitors, thiazides diuretics, or loop diuretics may have impaired response to these therapies when taking NSAIDs Monitor blood pressure (BP) during the initiation of NSAID treatment and throughout the course of therapy.The Coxib and traditional NSAID Trialists' Collaboration meta-analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. In a Danish National Registry study of patients with heart failure, NSAID use increased the risk of MI, hospitalization for heart failure, and death.Additionally, fluid retention and edema have been observed in some patients treated with NSAIDs.